Therapeutic access to cisplatin-resistant bladder cancer using VAR2-Drug Conjugates

Cisplatin is worldwide standard-of-care chemotherapy in muscle-invasive bladder cancer (MIBC). However, many patients develop resistance to cisplatin with no second-line treatment options currently available. A new study published on April 10, 2017 in European Urology demonstrates VAR2-mediated drug delivery as a putative second-line treatment strategy in cisplatin-resistant MIBC. Bladder cancer is the 5th most common cancer in North America, 4th most common among men and 12th most common among women.

Data published online April 11, 2017 in European Urology DOI